Cargando…
Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase
Imatinib mesylate (IM), an original Abl tyrosine kinase inhibitor, entered the clinics in 1998 for the treatment of patients with chronic myeloid leukemia (CML). The drug is universally considered the treatment of choice for most, if not all, patients with CML. Importantly, lessons learned from pati...
Autores principales: | Mughal, Tariq I, Schrieber, Andrew |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3010822/ https://www.ncbi.nlm.nih.gov/pubmed/21209726 http://dx.doi.org/10.2147/BTT.S5775 |
Ejemplares similares
-
Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase
por: Moura, Muriel Silva, et al.
Publicado: (2019) -
Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
por: Cortes, Jorge E., et al.
Publicado: (2016) -
Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
por: Linga, Vijay Gandhi, et al.
Publicado: (2014) -
Long-term outcomes of frontline imatinib therapy for chronic myeloid leukemia in China
por: Cheng, Fang, et al.
Publicado: (2023) -
Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)